Immunic, Inc.

Report azionario NasdaqCM:IMUX

Capitalizzazione di mercato: US$203.9m

Immunic Gestione

Criteri Gestione verificati 3/4

Immunic Il CEO è Daniel Vitt, nominato in Apr2019, e ha un mandato di 7.08 anni. la retribuzione annua totale è $ 2.31M, composta da 27.1% di stipendio e 72.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.29% delle azioni della società, per un valore di $ 586.64K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.8 anni e 5.5 anni.

Informazioni chiave

Daniel Vitt

Amministratore delegato

US$2.3m

Compenso totale

Percentuale dello stipendio del CEO27.05%
Mandato del CEO7.1yrs
Proprietà del CEO0.3%
Durata media del management4.8yrs
Durata media del Consiglio di amministrazione5.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

Articolo di analisi • Oct 17

We're A Little Worried About Immunic's (NASDAQ:IMUX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Jun 09

Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted

Summary Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results. We reiterate our Strong Buy rating, viewing the stock dip as a buying opportunity for investors with high-risk tolerance. Read the full article on Seeking Alpha
Seeking Alpha • Apr 28

Immunic: A Strong Buy With Imminent Data Readout That Should Send Shares Higher

Summary Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results and potential for commercialization if upcoming catalysts deliver. Despite high volatility and recent stock dilution, Immunic's market cap remains low, suggesting significant upside if clinical trials succeed. Vidofludimus calcium's unique dual action offers neuroprotection and anti-inflammatory benefits, positioning it as a potential next-gen oral MS treatment. Financial risks include ongoing cash burn and potential dilution, but management has a track record of successful fund-raising to support R&D efforts. Read the full article on Seeking Alpha
Articolo di analisi • Oct 25

We're Keeping An Eye On Immunic's (NASDAQ:IMUX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Articolo di analisi • Jan 22

Here's Why We're A Bit Worried About Immunic's (NASDAQ:IMUX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Oct 13

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Articolo di analisi • Jun 27

Will Immunic (NASDAQ:IMUX) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Oct 20

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Immunic (NASDAQ:IMUX) on Thursday said a phase 1b trial of its psoriasis treatment IMU-935 failed to separate from placebo, as measured by a reduction in the severity of the psoriatic lesions in the patients. Shares of the micro-cap clinical-stage biopharma plunged 73.7% to $2.49 after hours. A pre-planned interim analysis of the early-stage trial found a greater decrease than expected in the so-called Psoriasis Area and Severity Index (PASI) in the placebo arm. The PASI is a widely used instrument in psoriasis trials that evaluates and grades the severity of psoriatic lesions and the patient's response to treatment. The trial enrolled a total of 41 patients who were randomized to get 150 mg once-daily and 150 mg twice-daily doses of IMU-935, along with placebo. "At this point, the company only has access to very limited information. The interim analysis only revealed mean values at group-level up to the end of the four-week treatment period. Immunic does not yet have access to unblinded individual patient data," the company said in a statement. IMUX expects to continue IMU-935 development in psoriasis.
Seeking Alpha • Oct 10

Immunic stock gains on $60M oversubscribed PIPE financing

Immunic (NASDAQ:IMUX) shares gained as much as 21% premarket on Monday after the clinical-stage biopharmaceutical company announced a $60M oversubscribed private placement equity financing. The company entered into a securities purchase agreement with select accredited investors and certain existing investors to issue and sell an ~8.69M shares of its common stock at $4.35/share and pre-funded warrants to purchase up to 5,096,552 common shares at $4.34/pre-funded warrant share. The pre-funded warrants will be immediately exercisable at $0.01 per share of common stock and remain exercisable until exercised in full. Gross proceeds from the equity financing is estimated to be around $60M. The financing is expected to close on Oct 12, 2022. Net proceeds will be used to fund Immunic's (IMUX) ongoing clinical development of its three lead product candidates, vidofludimus calcium (IMU-838), IMU-935 and IMU-856, and for other general corporate purposes. Proceeds, along with current cash, cash equivalents and marketable securities, is expected to fund operating and capital expenditures into Q4/2024.
Seeking Alpha • Aug 04

Immunic GAAP EPS of -$0.72 in-line

Immunic press release (NASDAQ:IMUX): Q2 GAAP EPS of -$0.72 in-line. Cash and Cash Equivalents as of Q2  $88.1 million.
Articolo di analisi • Jul 27

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Daniel Vitt rispetto agli utili di Immunic?
DataCompenso totaleStipendioUtili della società
Mar 31 2026n/an/a

-US$104m

Dec 31 2025US$2mUS$625k

-US$97m

Sep 30 2025n/an/a

-US$103m

Jun 30 2025n/an/a

-US$102m

Mar 31 2025n/an/a

-US$96m

Dec 31 2024US$3mUS$610k

-US$101m

Sep 30 2024n/an/a

-US$97m

Jun 30 2024n/an/a

-US$95m

Mar 31 2024n/an/a

-US$98m

Dec 31 2023US$1mUS$585k

-US$94m

Sep 30 2023n/an/a

-US$129m

Jun 30 2023n/an/a

-US$127m

Mar 31 2023n/an/a

-US$125m

Dec 31 2022US$3mUS$520k

-US$120m

Sep 30 2022n/an/a

-US$85m

Jun 30 2022n/an/a

-US$83m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$2mUS$399k

-US$93m

Sep 30 2021n/an/a

-US$83m

Jun 30 2021n/an/a

-US$77m

Mar 31 2021n/an/a

-US$70m

Dec 31 2020US$1mUS$381k

-US$44m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$36m

Mar 31 2020n/an/a

-US$39m

Dec 31 2019US$2mUS$202k

-US$35m

Compensazione vs Mercato: La retribuzione totale di Daniel ($USD 2.31M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.59M ).

Compensazione vs guadagni: La retribuzione di Daniel è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Daniel Vitt (57 yo)

7.1yrs
Mandato
US$2,311,272
Compensazione

Dr. Daniel Vitt, PhD has been the Chief Executive Officer of Immunic, Inc. since April 2019 and also served as its President until July 12, 2024. He is also managing director of Immunic Research GmbH in Ha...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 586.6k
Jason Tardio
COO & President1.8yrsUS$1.21m0.0092%
$ 18.7k
Glenn Whaley
Chief Financial Officer6.1yrsUS$1.07m0.070%
$ 143.0k
Hella Kohlhof
Chief Scientific Officer9.3yrsNessun datoNessun dato
Jessica Breu
Vice President of Investor Relations & Communicationsno dataNessun datoNessun dato
Inderpal Singh
General Counsel4.9yrsNessun datoNessun dato
Patrick Walsh
Chief Business Officer4.6yrsNessun datoNessun dato
Werner Gladdines
Chief Development Officer1.8yrsNessun datoNessun dato
Michael A. Panzara
Chief Medical Officerless than a yearNessun datoNessun dato
4.8yrs
Durata media
54yo
Età media

Gestione esperta: Il team dirigenziale di IMUX è considerato esperto (durata media dell'incarico 4.8 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Daniel Vitt
CEO & Director7.1yrsUS$2.31m0.29%
$ 586.6k
Barclay Phillips
Lead Independent Director6.5yrsUS$171.98k0.11%
$ 233.5k
Michael Bonney
Chair of the Boardno dataNessun datoNessun dato
Tamar Howson
Independent Director6.6yrsUS$149.82k0.11%
$ 233.5k
Jorg Neermann
Independent Director7.1yrsUS$156.98k0.15%
$ 299.4k
Paul Utz
Member of Scientific Medical Advisory Board5.5yrsNessun datoNessun dato
Duane Nash
Director7.3yrsUS$982.95k0.026%
$ 53.9k
Bruce Sands
Member of Scientific Medical Advisory Board5.5yrsNessun datoNessun dato
Fred Lublin
Member of Scientific Medical Advisory Board5.5yrsNessun datoNessun dato
Richard Rudick
Independent Director3.1yrsUS$149.48k0.17%
$ 344.9k
Jon Congleton
Independent Directorless than a yearNessun datoNessun dato
Simona Skerjanec
Independent Director1.8yrsUS$149.14kNessun dato
5.5yrs
Durata media
62yo
Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IMUX sono considerati esperti (durata media dell'incarico 5.5 anni).

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/29 00:06
Prezzo dell'azione a fine giornata2026/05/29 00:00
Utili2026/03/31
Utili annuali2025/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Immunic, Inc. è coperta da 18 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
George FarmerBMO Capital Markets Equity Research
William WoodB. Riley Securities, Inc.
Tyler BussianBrookline Capital Markets